Drug Enforcement Administration July 2014 – Federal Register Recent Federal Regulation Documents

Meridian Medical Technologies applied to be registered as an importer of a certain basic class of narcotic controlled substance. The DEA grants Meridian Medical Technologies registration as an importer of this controlled substance.

With the issuance of this final rule, the Deputy Administrator of the Drug Enforcement Administration places the substance 2- [(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol (tramadol), including its salts, isomers, and salts of isomers, into schedule IV of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act which requires that such actions be made on the record after opportunity for a hearing through formal rulemaking. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule IV controlled substances on persons who handle (manufacture, distribute, dispense, import, export, engage in research, conduct instructional activities with, or possess) or propose to handle tramadol.